For research use only. Not for therapeutic Use.
Betahistine mesylate（Cat No.:I023299） is a biochemical compound with potential therapeutic applications in the treatment of peripheral vertigo. Peripheral vertigo refers to a type of dizziness caused by dysfunction in the inner ear. Betahistine mesylate acts by enhancing blood flow to the inner ear and balancing the release of histamine, a neurotransmitter involved in regulating vestibular function.
| Catalog Number | I023299 |
| CAS Number | 54856-23-4 |
| Synonyms | Betahistine mesilate; Betahistine mesylate; Extovyl; Meginalisk; Melopat; Merislon; Riptonin |
| Molecular Formula | C10H20N2O6S2 |
| Purity | 98% |
| Target | Neuronal Signaling |
| Solubility | To be determined |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 2-(Ethylammonio)-N-methylpyridinium dimethanesulphonate |
| InChI | InChI=1S/C8H12N2.2CH4O3S/c1-9-7-5-8-4-2-3-6-10-8;2*1-5(2,3)4/h2-4,6,9H,5,7H2,1H3;2*1H3,(H,2,3,4) |
| InChIKey | ZBJJDYGJCNTNTH-UHFFFAOYSA-N |
| SMILES | CNCCc1ccccn1.CS(=O)(=O)O.CS(=O)(=O)O |
| Reference | 1. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2016 Jun 21;2016(6):CD010696. doi: 10.1002/14651858.CD010696.pub2. PMID: 27327415; PMCID: PMC7388750. |
